Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study

Authors:

Abstract
Introduction: A once-daily (o.d.) fixed-dose combination of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) via Breezhaler® device demonstrated improved lung function vs twice-daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) via Diskus® in patients with inadequately controlled asthma (IRIDIUM: NCT02571777). Differences in asthma severity and treatment effects between men and women have been reported. We assessed the effect of gender on the efficacy and safety of MF/IND/GLY o.d. (medium-dose 80/150/50 μg; high-dose 160/150/50 μg) vs FLU/SAL b.i.d. (high-dose 500/50 μg). Methods: Symptomatic asthmatics (ACQ-7 ≥1.5), aged 18–75 years, with ≥1 exacerbation in last year, predicted FEV1 1, ACQ-7 score, rescue medication use (Wk 26); rate of exacerbations, safety (Wk 52); stratified by gender (men, 1174; women, 1918) from randomised population. Interaction P-values denote effect of gender on treatment. Results: Medium- and high-dose MF/IND/GLY o.d. improved trough FEV1 in both genders vs high-dose FLU/SAL b.i.d. (Table). As for ACQ-7 scores, rescue medication use, rate of exacerbations and safety, treatment effects were consistent across genders with MF/IND/GLY vs FLU/SAL. Conclusions: Medium- or high-dose MF/IND/GLY o.d. improved lung function vs high-dose FLU/SAL b.i.d., independent of gender.